Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus

Obesity

Volumn 25, Issue 5, 2017, Pages 842-849

  Magkos, Faidon ^a   Nikonova, Elena ^b   Fain, Randi ^c   Zhou, Sharon ^b   Ma, Tony ^d   Shanahan, William ^e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b EISAI INC   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e Anthera Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; LORCASERIN; MEGLITINIDE; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; BENZAZEPINE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; WEIGHT REDUCTION; ADOLESCENT; AGED; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZAZEPINES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85016639741     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21798     Document Type: Article

References (35)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292.
2. Jensen MD, Ryan DH, Donato KA, et al. Executive Summary: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring) 2014;22(Suppl S2):S5-S39.
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: US Department of Health and Human Services; 2014.
4. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29. doi:10.1186/1478-7954-8-29
5. Narayan KMV, Zhang P, Kanaya AM, et al. Diabetes: The pandemic and potential solutions. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., eds. Disease Control Priorities in Developing Countries. 2nd ed. Washington, DC: World Bank; 2006.
6. Manuel DG, Schultz SE. Health-related quality of life and health-adjusted life expectancy of people with diabetes in Ontario, Canada, 1996-1997. Diabetes Care 2004;27:407-414.
7. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-1890.
8. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-339.
9. Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004;53:1066-1068.
10. Standards of medical care in diabetes—2014. Diabetes Care 2014;37(Suppl 1):S14-S80.
11. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006;444:840-846.
12. Kushner RF, Ryan DH. Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. JAMA 2014;312:943-952.
13. Ryan D, Heaner M. Guidelines (2013) for managing overweight and obesity in adults. Preface to the full report. Obesity (Silver Spring) 2014;22(Suppl 2):S1-S3.
14. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86.
15. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology 2007;132:2226-2238.
16. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-154.
17. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014;5:135-148.
18. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014;95:53-66.
19. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine(2C) agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 2008;325:577-587.
20. Xu Y, Jones JE, Kohno D, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 2008;60:582-589.
21. Xu Y, Berglund ED, Sohn JW, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver. Nat Neurosci 2010;13:1457-1459.
22. BELVIQ (lorcaserin hydrochloride) US Prescribing Information. 2014. Woodcliff Lake, NJ: Eisai Inc.
23. Rothman RB, Baumann MH, Savage JE, et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000;102:2836-2841.
24. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256.
25. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-3077.
26. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-1436.
27. Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med 2014;126:7-18.
28. Wing RR, Bahnson JL, Bray GA, et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010;170:1566-1575.
29. Smith SR, O'Neil PM, Astrup A, et al. Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014;22:2137-2146.
30. Fabricatore AN, Wadden TA, Moore RH, et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10:333-341.
31. Pi-Sunyer X, Shanahan W, Fain R, Ma T, Garvey WT. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med 2016;128:591-597.
32. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The A1C test and diabetes. https://www.niddk.nih.gov/health-information/health-topics/diagnostic-tests/a1c-test-diabetes/Pages/index.aspx. Published September 2014. Accessed July 27, 2016.
33. Trepanowski JF, Canale RE, Marshall KE, Kabir MM, Bloomer RJ. Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings. Nutr J 2011;10:107. doi:10.1186/1475-2891-10-107
34. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
35. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care 2008;31:2086-2091.